Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Stomach Neoplasms;Breast Neoplasms, Date of authorisation: 12/12/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Stomach Neoplasms;Breast Neoplasms, Date of authorisation: 12/12/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Kirsty (previously Kixelle), insulin aspart, Diabetes Mellitus, Date of authorisation: 05/02/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Kirsty (previously Kixelle), insulin aspart, Diabetes Mellitus, Date of authorisation: 05/02/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Hidradenitis Suppurativa;Psoriasis;Uveitis;Arthritis, Rheumatoid;Spondylitis, Ankylosing;Crohn Disease;Colitis, Ulcerative;Arthritis, Psoriatic, Date of authorisation: 17/09/201

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Hidradenitis Suppurativa;Psoriasis;Uveitis;Arthritis, Rheumatoid;Spondylitis, Ankylosing;Crohn Disease;Colitis, Ulcerative;Arthritis, Psoriatic, Date of authorisation: 17/09/2018, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Tuberculosis, Multidrug-Resistant, Date of authorisation: 31/07/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Tuberculosis, Multidrug-Resistant, Date of authorisation: 31/07/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Adcetris, brentuximab vedotin, Lymphoma, Non-Hodgkin;Hodgkin Disease, Date of authorisation: 25/10/2012, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Adcetris, brentuximab vedotin, Lymphoma, Non-Hodgkin;Hodgkin Disease, Date of authorisation: 25/10/2012, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic;Psoriasis, Date of authorisation: 15/01/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic;Psoriasis, Date of authorisation: 15/01/2015, Revision: 21, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.